T-2307 causes collapse of mitochondrial membrane potential in yeast.
about
Emerging drugs and vaccines for candidemiaSynergistic combinations of antifungals and anti-virulence agents to fight against Candida albicansA vanillin derivative causes mitochondrial dysfunction and triggers oxidative stress in Cryptococcus neoformansCryptococcal meningitis: A neglected NTD?Pooled segregant sequencing reveals genetic determinants of yeast pseudohyphal growth.Antitumor/Antifungal Celecoxib Derivative AR-12 is a Non-Nucleoside Inhibitor of the ANL-Family Adenylating Enzyme Acetyl CoA Synthetase.The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrataCryptococcus: from environmental saprophyte to global pathogen.A complex game of hide and seek: the search for new antifungalsAntifungals: Mechanism of Action and Drug Resistance.Sodium ascorbate kills Candida albicans in vitro via iron-catalyzed Fenton reaction: importance of oxygenation and metabolism.Systemic Antifungal Agents: Current Status and Projected Future Developments.Combination therapy for the treatment of pulmonary mold infections.The anti-Aspergillus drug pipeline: Is the glass half full or empty?The antifungal pipeline: a reality check.Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.T-2307, a novel arylamidine, is transported into Candida albicans by a high-affinity spermine and spermidine carrier regulated by Agp2.Antifungal resistance: current trends and future strategies to combat.New Horizons in Antifungal Therapy.
P2860
Q26828993-A084790E-B38A-4C16-ADD0-AC522F8FCD50Q28082407-A04F6720-191D-4FB0-BCAF-4B8DBA16733CQ28539994-00E02C89-3877-44A8-A866-3EB006A5030AQ33852819-3F08A939-B850-4942-8A85-F3530AE6ADEEQ34075109-3A40559D-8B3F-499C-8911-C5F3668B873DQ34522517-1BC0EA01-1E7C-42F1-AD11-C7092D630B58Q34540684-A07058AC-14E8-4B88-B663-1E67066DDE0AQ35105818-17922EEF-D5B7-42CE-9665-2172AD57689CQ36551326-2781C10A-FE16-40AF-AEC4-C41B762267E6Q37250158-87EF28BC-293C-462F-85F1-6D3EA069333BQ37344546-E12406AF-49FF-419F-9EB8-30542FBC241DQ38684281-9F87BCA6-0D9E-45B5-B2AE-F611421D9250Q38794452-6F23CA99-4CE6-472E-9680-30E5CE3040E5Q38796140-C35089C4-9A7D-4406-A9D7-CBBD72D02FAEQ38806932-EE0C2279-91BC-4E00-BEFE-2975057FB567Q38937577-9142339E-4CC4-436D-B473-A8D0E39A54E2Q39299949-30A042C8-9438-48F1-B8B9-31562C3B9B68Q40045666-53DE52D1-6515-4B77-8D7D-487562FE4E50Q40111798-61AB08CD-1C4C-4946-BFE9-1469A1107ACFQ40332083-D605F7BA-B00F-403B-AE65-E767A533A080Q40709545-A30F4899-1943-431B-A05D-901ED9AFF06DQ41632930-5F6B8DAD-1F8E-404E-B11E-DADE0315E191Q48149179-D94EBA3E-0F6A-4CB4-8A19-E7A5C8857828
P2860
T-2307 causes collapse of mitochondrial membrane potential in yeast.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
T-2307 causes collapse of mitochondrial membrane potential in yeast.
@en
type
label
T-2307 causes collapse of mitochondrial membrane potential in yeast.
@en
prefLabel
T-2307 causes collapse of mitochondrial membrane potential in yeast.
@en
P2093
P2860
P356
P1476
T-2307 causes collapse of mitochondrial membrane potential in yeast.
@en
P2093
Akiko Kimura
Eio Yamada
Hiroshi Nishikawa
Hiroyoshi Hayakawa
Junichi Mitsuyama
Nobuhiko Nomura
Tatsuya Shibata
Toshinari Takahashi
P2860
P304
P356
10.1128/AAC.05954-11
P407
P577
2012-09-04T00:00:00Z